Hallym University Chuncheon Sacred Heart Hospital (President Lee Jae-jun) a annoncé le 29th that it récemment signed a protocole d'accord (MOU) with the Hallym University Medical Bio Convergence Research Institute, IonCell Co., Ltd. (le PDG Kim Hyung-soo), and RudaCure Inc. (PDG Yongho Kim) for recherche conjointe on CAR-T and ADC drugs.
This MOU a été établi to integrate the core technologies and capabilities of each institution afin de develop effective thérapeutiques and, further, to contribute to the advancement of the medical bio industrie at both the regional and national levels.
The specific terms of the accord include: 1) mutual sharing of expertise and technology between the institutions; 2) développement conjoint of CAR-T and ADC drugs; and 3) provision of innovant treatments and therapies to patients. Grâce à cela accord, the core technologies and infrastructure of each institution—notamment the excellent données cliniques held by Hallym University Chuncheon Sacred Heart Hospital, the drug screening technology of IonCell Co., Ltd., and the drug efficacy evaluation and thérapeutique development technology of RudaCure Inc.—devraient generate synergies. The recherche conjointe will visent à develop thérapeutiques utilizing Chimeric Antigen Receptor T-cell (CAR-T) technology and treatments sur la base de Antibody-Drug Conjugates (ADC), referred to as a next-generation cancer treatment technology.
* Sources
[Edaily] https://www.edaily.co.kr/news/read?newsId=01449766635843440&mediaCodeNo=257
[Uigye Sinmun] https://www.medworld.co.kr/news/articleView.html?idxno=227581